Neoadjuvant Durvalumab/Anlotinib /Chemotherapy Plus Curative Resection in Stage III Non-Small-Cell Lung Cancer : A Single-arm Phase II Study
This is a randomized, open label study designed to evaluate the efficacy and safety of neoadjuvant Durvalumab/Anlotinib/Chemotherapy followed by surgery in resectable stage III non-small cell lung cancer.
Non Small Cell Lung Cancer
DRUG: Durvalumab Anlotinib Carboplatin Nab-paclitaxel
PFS at 24 months, The PFS is defined as the time from diagnosis to relapse, progression or death, whichever occurred first., From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months
This is a randomized, open label study designed to evaluate the efficacy and safety of neoadjuvant Durvalumab/Anlotinib/Chemotherapy followed by surgery in resectable stage III non-small cell lung cancer.